SHERMAN MARK ANDREW
SEC CIK 1256708 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| DLB | Dolby Laboratories, Inc. | EVP, Gen. Counsel, Sec | 119.0K | — | $13.25M | 39 | 2020-12-16 | 2026-09-15 |
Most active insiders at DLB, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | YEAMAN KEVIN J | Pres, CEO, Dir | — | $8.72M |
| 2 | Couling John D | SVP, Entertainment | — | $3.82M |
| 3 | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | — | $1.08M |
| 4 | Revankar Shriram | SVP, Advanced Technology Group | — | $747.9K |
| 5 | Pendleton Todd | SVP, CMO | — | $647.9K |
| 6 | Nicholson Ryan | VP, CAO, Corp. Ctrl | — | $359.5K |
| 7 | Park Robert J | SVP, CFO | — | $277.4K |
| 8 | Prophet Tony A | Dir | — | $223.9K |
| 9 | Rollins Emily | Dir | — | $60.1K |
| 10 | Whitten Marc | Pres, CEO, Dir | — | — |
Transactions 39
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-17 17:03 | 2026-09-15 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | A - Grant | $0.00 | +48.1K | 119.0K | +68% | $0 | |
| DMT | 2025-12-17 | 2025-12-16+ | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | S - Sale+OE | $66.85 | -11.6K | 75.4K | -13% | -$775.4K |
| DMT | 2025-12-17 | 2025-12-15+ | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | F - Tax | $67.34 | -11.8K | 84.7K | -12% | -$793.4K |
| DT | 2025-12-17 | 2025-12-15 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | M - OptEx | $0.00 | +5,915 | 93.9K | +7% | $0 |
| DT | 2025-12-17 | 2025-12-15 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | A - Grant | $0.00 | +25.6K | 88.0K | +41% | $0 |
| DT | 2025-12-03 | 2025-12-01 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | M - OptEx | $64.60 | +4,500 | 66.9K | +7% | +$290.7K |
| DT | 2025-12-03 | 2025-12-01 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | S - Sale+OE | $67.56 | -4,500 | 62.4K | -7% | -$304.0K |
| DT | 2025-06-06 | 2025-06-04 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | M - OptEx | $64.60 | +15.0K | 77.4K | +24% | +$969.0K |
| DT | 2025-06-06 | 2025-06-04 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | S - Sale+OE | $75.02 | -15.0K | 62.4K | -19% | -$1.13M |
| T | 2025-06-03 | 2025-05-30 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | S - Sale | $74.97 | -350 | 62.4K | -0.6% | -$26.2K |
| DT | 2025-02-03 | 2025-01-30 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | M - OptEx | $62.32 | +40.0K | 102.4K | +64% | +$2.49M |
| DMT | 2025-02-03 | 2025-01-30 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | S - Sale+OE | $84.88 | -40.0K | 87.4K | -31% | -$3.40M |
| DMT | 2024-12-18 | 2024-12-17 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | S - Sale+OE | $78.07 | -12.3K | 70.1K | -15% | -$963.3K |
| DT | 2024-12-18 | 2024-12-16 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | F - Tax | $79.18 | -8,867 | 74.7K | -11% | -$702.1K |
| DT | 2024-12-18 | 2024-12-16 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | A - Grant | $0.00 | +20.1K | 78.4K | +34% | $0 |
| DT | 2024-12-18 | 2024-12-16 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | M - OptEx | $0.00 | +5,192 | 83.6K | +7% | $0 |
| DT | 2024-05-30 | 2024-05-28 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | S - Sale+OE | $79.62 | -2,283 | 58.3K | -4% | -$181.8K |
| DT | 2024-05-30 | 2024-05-28 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | M - OptEx | $62.32 | +1,998 | 60.6K | +3% | +$124.5K |
| D | 2023-12-19 | 2023-12-15 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | A - Grant | $0.00 | +16.7K | 73.5K | +29% | $0 |
| D | 2023-12-19 | 2023-12-15 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | M - OptEx | $0.00 | +5,738 | 79.2K | +8% | $0 |
| DM | 2023-12-19 | 2023-12-15+ | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | F - Tax | $88.42 | -10.3K | 68.8K | -13% | -$915.2K |
| DM | 2023-12-19 | 2023-12-18+ | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | S - Sale+OE | $86.16 | -10.5K | 58.3K | -15% | -$906.3K |
| D | 2023-07-14 | 2023-07-12 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | M - OptEx | $62.32 | +21.0K | 77.7K | +37% | +$1.31M |
| D | 2023-07-14 | 2023-07-12 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | S - Sale+OE | $89.00 | -21.0K | 56.7K | -27% | -$1.87M |
| DM | 2023-05-10 | 2023-05-08 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | M - OptEx | $49.85 | +15.0K | 71.4K | +27% | +$747.8K |
| DM | 2023-05-10 | 2023-05-08 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | S - Sale+OE | $83.60 | -15.0K | 56.4K | -21% | -$1.25M |
| D | 2023-02-07 | 2023-02-03 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | M - OptEx | $45.50 | +12.0K | 70.8K | +20% | +$546.0K |
| DM | 2023-02-07 | 2023-02-03+ | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | S - Sale+OE | $84.77 | -14.4K | 58.8K | -20% | -$1.22M |
| 2022-12-22 | 2022-12-20 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, GEN. COUN, SECRTY | S - Sale | $68.09 | -1,638 | 58.8K | -3% | -$111.5K | |
| DM | 2022-12-19 | 2022-12-15+ | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, GEN. COUN, SECRTY | F - Tax | $71.70 | -7,696 | 69.4K | -10% | -$551.8K |
| D | 2022-12-19 | 2022-12-16 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, GEN. COUN, SECRTY | M - OptEx | $0.00 | +5,344 | 73.0K | +8% | $0 |
| DM | 2022-12-19 | 2022-12-16+ | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, GEN. COUN, SECRTY | S - Sale+OE | $70.10 | -7,404 | 67.1K | -10% | -$519.0K |
| D | 2022-12-19 | 2022-12-15 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, GEN. COUN, SECRTY | A - Grant | $0.00 | +18.3K | 67.7K | +37% | $0 |
| 2022-02-09 | 2022-02-09 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, GEN. COUN, SECRTY | S - Sale | $77.23 | -1,798 | 51.6K | -3% | -$138.9K | |
| M | 2021-12-20 | 2021-12-17+ | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, GEN. COUN, SECRTY | S - Sale | $90.43 | -3,301 | 55.0K | -6% | -$298.5K |
| 2021-12-20 | 2021-12-17 | DLB | Dolby Laboratories, Inc. | SHERMAN MARK ANDREW | EVP, GEN. COUN, SECRTY | F - Tax | $92.00 | -1,612 | 56.7K | -3% | -$148.3K | |
| DM | 2021-12-16 | 2020-12-16 | DLB | Dolby Laboratories, Inc. | EVP, GEN. COUN, SECRTY | S - Sale | $91.15 | -1,764 | 58.6K | -3% | -$160.8K | |
| DM | 2021-12-16 | 2020-12-16+ | DLB | Dolby Laboratories, Inc. | EVP, GEN. COUN, SECRTY | F - Tax | $90.95 | -5,143 | 47.0K | -10% | -$467.7K | |
| D | 2021-12-16 | 2021-12-15 | DLB | Dolby Laboratories, Inc. | EVP, GEN. COUN, SECRTY | A - Grant | $0.00 | +14.8K | 61.7K | +31% | $0 |
Purchase Sale Sale after option exercise All abbreviations